Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 8, Pages 1702-1712
Publisher
Springer Nature
Online
2015-04-17
DOI
10.1038/leu.2015.99
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
- (2015) J Flynn et al. LEUKEMIA
- Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era
- (2014) R. Vaidya et al. ANNALS OF ONCOLOGY
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience
- (2014) Yasuhiro Oki et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abstract 699: Optimized dosing strategies resulting in prolonged pathway inhibition enhance dinaciclib anti-tumor activity in preclinical xenograft models.
- (2014) Alwin Schuller et al. CANCER RESEARCH
- Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
- (2014) G. L. Kelly et al. GENES & DEVELOPMENT
- BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma
- (2014) Samantha L. Kendrick et al. HUMAN PATHOLOGY
- Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy
- (2014) Elisa Oricchio et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
- (2014) Robert N. Booher et al. PLoS One
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
- (2013) H. Horn et al. BLOOD
- Programming cancer cells for high expression levels of Mcl1
- (2013) Franziska Ertel et al. EMBO REPORTS
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
- (2013) Anupkumar George et al. LEUKEMIA & LYMPHOMA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
- (2012) Guo Wei et al. CANCER CELL
- Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma
- (2012) Stefano Monti et al. CANCER CELL
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
- (2012) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma
- (2012) S-S Wenzel et al. LEUKEMIA
- The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma
- (2011) Elisa Oricchio et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma
- (2011) Jonathan H. Schatz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
- (2011) K A Blum et al. LEUKEMIA
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2011) J. W. Friedberg Hematology-American Society of Hematology Education Program
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
- (2009) Rong Chen et al. BLOOD
- SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
- (2009) Andrew Conroy et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
- (2008) Alessia Montagnoli et al. Nature Chemical Biology
- mTORC1 promotes survival through translational control of Mcl-1
- (2008) J. R. Mills et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started